SLD Shares Saluda Medical, Inc.
BUY ASX · ASXBroker-backed turnaround potential and consumer healthcare exposure provide asymmetric speculative upside.
Signal breakdown
- ▸Morgans speculative buy rating with $2.17 target
- ▾Below 50-day MA (-41.63%)
- ▾Near 52-week low (0% of range)
Is SLD a buy right now?
Trend: SLD is trading below the 50-day average (-36.90%), RSI 30 — oversold territory, with a 3-month return of -36.90%.
Valuation & quality: Saluda Medical, Inc. trades on forward P/E -0.7, price-to-book 0.86; fundamentals show net margin -165.9%, revenue growth 38.4% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$1.66 (+564% vs the last close; range A$1.30 – A$2.06), consensus rating “strong buy”.
Our screen: BUY (score 2) — Broker-backed turnaround potential and consumer healthcare exposure provide asymmetric speculative upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -24.00% | -24.10% | -40.00% | +27.80% | -4.30% | +6.80% | -12.80% | -36.60% |
Fundamentals
Analyst price target
Technical signals
About Saluda Medical, Inc.
Saluda Medical, Inc., a medical device company, develops treatments for chronic neurological conditions in the United States, Australia, Europe, and internationally.
Sector: Healthcare · Industry: Medical Devices · United States · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.